Clinical Trials Logo

Pancreatic Adenocarcinoma clinical trials

View clinical trials related to Pancreatic Adenocarcinoma.

Filter by:

NCT ID: NCT00593008 Terminated - Clinical trials for Pancreatic Adenocarcinoma

Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

Start date: October 2007
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to try to define the highest doses of temsirolimus and gemcitabine that can be used safely in combination to treat advanced pancreatic cancer. Gemcitabine is a standard chemotherapy used for the treatment of pancreatic cancer.

NCT ID: NCT00574977 Completed - Breast Cancer Clinical Trials

Safety Study of Modified Vaccinia Virus to Cancer

Start date: May 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and maximum tolerated dose from injecting this vaccinia virus into tumors or infusion.

NCT ID: NCT00327327 Completed - Clinical trials for Pancreatic Adenocarcinoma

Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma

Start date: February 2004
Phase: Phase 1
Study type: Interventional

AMP-004 is a Phase 1b dose escalation trial designed to evaluate the safety of the new drug imexon in combination with an approved drug, gemcitabine, for the treatment of patients with previously untreated pancreatic cancer. The treatment consists of dosing with both imexon and gemcitabine on days 1, 8, and 15 of each 28 day cycle. The study is designed to determine the highest doses of the two drugs that can be safely combined together.

NCT ID: NCT00288093 Completed - Clinical trials for Pancreatic Adenocarcinoma

3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery

Start date: December 20, 2006
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of 3-AP when given together with radiation therapy in treating patients with stage III pancreatic cancer that cannot be removed by surgery. 3-AP may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. 3-AP may make tumor cells more sensitive to radiation therapy. Giving 3-AP together with radiation therapy may kill more tumor cells.

NCT ID: NCT00203892 Completed - Clinical trials for Pancreatic Adenocarcinoma

Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma

Start date: April 2003
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether the experimental vaccine "modified CEA peptide CAP 1 -6D" (mCEA) can produce an immune response in patients with pancreatic cancer who have received chemotherapy and radiation therapy.

NCT ID: NCT00154791 Completed - Clinical trials for Pancreatic Adenocarcinoma

Phase I/II Trial GOFL in Advanced Pancreatic Adenocarcinoma

Start date: March 2003
Phase: Phase 1/Phase 2
Study type: Interventional

We plan to conduct a phase I/II clinical trial using biweekly gemcitabine, oxaliplatin, and 48-hour infusion of high dose 5-FU/leucovorin to treat patients with advanced pancreatic adenocarcinoma. In the phase I part, the maximum tolerable dose of oxaliplatin in combination with biweekly gemcitabine 800 mg/m2 and 48-hour infusion of 5-FU 3000 mg/m2 and leucovorin 300 mg/m2 will be determined. In the phase II part, the efficacy and safety of the biweekly chemotherapy with GOFL will be evaluated.